31240 Federal Register / Vol. 87, No. 99 / Monday, May 23, 2022 / Notices 

implementation as well as short term 

and intermediate outcomes of the 

thirteen funded recipients. 

CDC and RTI International propose to 

collect information from all thirteen 

funded PCNASP recipients to gain 

insight into the effectiveness of 

implementation approaches, including 

linking and using data, using team 

based approaches to coordinate stroke 

care, and providing community 

resources in order to reach the general 

population and those at highest risk of 

stroke events, and reduce disparities in 

access to quality care for high burden 

populations. 

The information collection will focus 

on describing PCNASP specific 

contributions to effective state-based 

stroke systems of care and the costs 

associated with this work. Two 

components of the information 

collection include: (1) Program 

implementation cost data collection 

from program recipients using a cost 

collection tool; and (2) interviews with 

key program and partner staff. Cost data 

collection will focus on recipients’ 

cumulative spending to support 

PCNASP activities, spending by 

reporting period, and spending 

associated with specific PCNASP 

strategies related to building 

comprehensive state-wide stroke 

systems of care and strategies focusing 

on high-risk populations. Interview 

questions will focus on how each 

recipient implemented its strategies to 

increase access to and quality of 

healthcare overall, as well as for 

patients at highest risk of stroke events. 

It will identify challenges encountered 

and how they were overcome, factors 

that facilitated implementation, lessons 

learned along the way, and observed 

outcomes and improvements. The 

information to be collected does not 

currently exist for large scale, statewide 

programs that employ multiple 

combinations of strategies to build 

comprehensive stroke systems of care. 

The insights to be gained from this 

data collection will be critical to 

improving immediate efforts and 

achieving the goals of spreading and 

replicating state-level strategies that are 

proven programmatically and are costeffective in contributing to a higher 

quality of care for stroke patients. OMB 

approval is requested for three years. 

CDC requests OMB approval for an 

estimated 104 annual burden hours. 

Participation is voluntary and there are 

no costs to respondents other than their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Program Manager ............................. Cost Collection Tool ......................... 13 1 2 26 

Program Director ............................... Interview ........................................... 13 1 1 13 

Quality Improvement Specialist ........ Interview ........................................... 13 1 1 13 

Partner Support Staff ........................ Interview ........................................... 52 1 1 52 

Total ........................................... ........................................................... ........................ ........................ ........................ 104 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–10992 Filed 5–20–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, 

National Center for Injury Prevention 

and Control 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

for the Board of Scientific Counselors, 

National Center for Injury Prevention 

and Control (BSC, NCIPC). This meeting 

is closed to the public. 

DATES: The meeting will be held on June 

8, 2022, from 1 p.m. to 4 p.m., EDT 

(CLOSED). 

ADDRESSES: Zoom Virtual Meeting. 

FOR FURTHER INFORMATION CONTACT: 

Arlene Greenspan, DrPH, MPH, PT, 

Associate Director for Science, NCIPC, 

CDC, 4770 Buford Highway NE, 

Mailstop S–1069, Atlanta, Georgia 

30341, Telephone: (770) 488–1279, 

Email: ncipcbsc@cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

meeting designated above will be closed 

to the public in accordance with 

provisions set forth in Section 

552b(c)(4) and (6), Title 5 U.S.C., and 

the Determination of the Director, 

Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, 

CDC, pursuant to Public Law 92–463 (5 

U.S.C. App. 2). 

Purpose: The Board will: (1) Conduct, 

encourage, cooperate with, and assist 

other appropriate public health 

authorities, scientific institutions, and 

scientists in the conduct of research, 

investigations, experiments, 

demonstrations, and studies relating to 

the causes, diagnosis, treatment, control, 

and prevention of physical and mental 

diseases, and other impairments; (2) 

assist States and their political 

subdivisions in preventing and 

suppressing communicable and noncommunicable diseases and other 

preventable conditions and in 

promoting health and well-being; and 

(3) conduct and assist in research and 

control activities related to injury. The 

Board of Scientific Counselors makes 

recommendations regarding policies, 

strategies, objectives, and priorities; and 

reviews progress toward injury 

prevention goals and provides evidence 

in injury prevention-related research 

and programs. The Board also provides 

advice on the appropriate balance of 

intramural and extramural research, as 

well as the structure, progress and 

performance of intramural programs. 

The Board is designed to provide 

guidance on extramural scientific 

program matters, including the: (1) 

Review of extramural research concepts 

for funding opportunity 

announcements; (2) conduct of 

Secondary Peer Review of extramural 

research grant, cooperative agreement, 

and contract applications received in 

response to funding opportunity 

announcements as they relate to the 

Center’s programmatic balance and 

mission; (3) submission of secondary 

review recommendations to the Center 

Director of applications to be considered 

for funding support; (4) review of 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 99 / Monday, May 23, 2022 / Notices 31241 

research portfolios, and (5) review of 

program proposals. 

Matters to be Considered: The closed 

meeting will focus on the Secondary 

Peer Review of extramural research 

grant applications received in response 

to two (2) Notice of Funding 

Opportunities (NOFOs): (1) RFA–CE– 

22–002—‘‘Grants to Support New 

Investigators in Conducting Research 

Related to Preventing Interpersonal 

Violence Impacting Children and 

Youth’’; (2) RFA–CE–22–004— 

‘‘Research Grants to Prevent FirearmRelated Violence and Injuries (R01)’’; as 

well as PA–21–259—PHS 2021–2 

Omnibus Solicitation of the NIH, CDC 

and FDA for Small Business Innovation 

Research (SBIR) Grant Applications 

(Parent SBIR [R43/R44] Clinical Trial 

Not Allowed) and PA–21–260—PHS 

2021–2 Omnibus Solicitation of the NIH 

and CDC for SBIR Grant Applications 

(Parent SBIR [R43/R44] Clinical Trial 

Required). Agenda items are subject to 

change as priorities dictate. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–10944 Filed 5–20–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3428–PN] 

Medicare and Medicaid Programs: 

Application From the National Dialysis 

Accreditation Commission (NDAC) for 

Continued Approval of Its End Stage 

Renal Disease (ESRD) Facility 

Accreditation Program 

AGENCY: Centers for Medicare and 

Medicaid Services, HHS. 

ACTION: Notice with request for 

comment. 

SUMMARY: This notice acknowledges the 

receipt of an application from the 

National Dialysis Accreditation 

Commission for continued recognition 

as a national accrediting organization 

for End Stage Renal Disease facilities 

that wish to participate in the Medicare 

or Medicaid programs. 

DATES: To be assured consideration, 

comments must be received at one of 

the addresses provided below, no later 

than 5 p.m. on June 22, 2022. 

ADDRESSES: In commenting, refer to file 

code CMS–3428–PN. Because of staff 

and resource limitations, we cannot 

accept comments by facsimile (FAX) 

transmission. 

Comments, including mass comment 

submissions, must be submitted in one 

of the following three ways (please 

choose only one of the ways listed): 

1. Electronically. You may submit 

electronic comments on this regulation 

to http://www.regulations.gov. Follow 

the ‘‘Submit a comment’’ instructions. 

2. By regular mail. You may mail 

written comments to the following 

address ONLY: Centers for Medicare & 

Medicaid Services, Department of 

Health and Human Services, Attention: 

CMS–3428–PN, P.O. Box 8010, 

Baltimore, MD 21244–8010. 

Please allow sufficient time for mailed 

comments to be received before the 

close of the comment period. 

3. By express or overnight mail. You 

may send written comments to the 

following address ONLY: Centers for 

Medicare & Medicaid Services, 

Department of Health and Human 

Services, Attention: CMS–3428–PN, 

Mail Stop C4–26–05, 7500 Security 

Boulevard, Baltimore, MD 21244–1850. 

For information on viewing public 

comments, see the beginning of the 

SUPPLEMENTARY INFORMATION section. 

FOR FURTHER INFORMATION CONTACT: 

Caecilia Blondiaux, (410) 786–2190. 

SUPPLEMENTARY INFORMATION: 

Inspection of Public Comments: All 

comments received before the close of 

the comment period are available for 

viewing by the public, including any 

personally identifiable or confidential 

business information that is included in 

a comment. We post all comments 

received before the close of the 

comment period on the following 

website as soon as possible after they 

have been received: http://

www.regulations.gov. Follow the search 

instructions on that website to view 

public comments. 

I. Background 

Under the Medicare program, eligible 

beneficiaries may receive covered 

services from an end-stage renal disease 

(ESRD) facility provided certain 

requirements are met. Section 1881(b) of 

the Social Security Act (the Act) 

establishes distinct criteria for facilities 

seeking designation as a Medicarecertified ESRD facility. Regulations 

concerning provider agreements are at 

42 CFR part 489 and those pertaining to 

activities relating to the survey and 

certification of facilities are at 42 CFR 

part 488. The regulations at 42 CFR part 

494 subparts A through D specify the 

conditions that an ESRD must meet in 

order to participate in the Medicare 

program, the scope of covered services, 

and the conditions for Medicare 

payment for ESRD facilities. 

Generally, to enter into an agreement, 

an ESRD facility must first be certified 

by a State survey agency as complying 

with the conditions or requirements set 

forth in part 494 subparts A through D 

of our Medicare regulations. Thereafter, 

the ESRD facility is subject to regular 

surveys by a State survey agency to 

determine whether it continues to meet 

these requirements. 

Section 1865(a)(1) of the Act provides 

that, if a provider entity demonstrates 

through accreditation by a Centers for 

Medicare & Medicaid Services (CMS) 

approved national accrediting 

organization (AO) that all applicable 

Medicare conditions are met or 

exceeded, we may deem those provider 

entities as having met the requirements. 

Accreditation by an AO is voluntary and 

is not required for Medicare 

participation. 

If an AO is recognized by the 

Secretary of the Department of Health 

and Human Services (the Secretary) as 

having standards for accreditation that 

meet or exceed Medicare requirements, 

any provider entity accredited by the 

national accrediting body’s approved 

program would be deemed to meet the 

Medicare conditions. A national AO 

applying for approval of its 

accreditation program under part 488, 

subpart A, must provide CMS with 

reasonable assurance that the AO 

requires the accredited provider entities 

to meet requirements that are at least as 

stringent as the Medicare conditions. 

Our regulations concerning the approval 

of AOs are set forth at § 488.4 and 488.5. 

The regulations at § 488.5(e)(2)(i) 

require AOs to reapply for continued 

approval of its accreditation program 

every 6 years or sooner as determined 

by CMS. 

The National Dialysis Accreditation 

Commission’s (NDAC’s) current term of 

approval for their ESRD facility 

accreditation program expires January 4, 

2023. 

II. Approval of Deeming Organizations 

Section 1865(a)(2) of the Act and 

regulations at § 488.5 require that our 

findings concerning review and 

approval of an AO’s requirements 

consider, among other factors, the 


lotter on DSK11XQN23PROD with NOTICES1